



Biotech Daily

Monday October 18, 2021

Daily news on ASX-listed biotechnology companies

- * **ASX UP, BIOTECH DOWN: PROTEOMICS UP 12%; COMPUMEDICS DOWN 7%**
- * **PACIFIC EDGE 'OVERSUBSCRIBED' PLAN RAISES \$22m; TOTAL \$99.9m**
- * **ALCIDION, SYDNEY HEALTH \$1.8m TELE-HEALTH CONTRACT**
- * **HERAMED NOTES RAISE \$2.4m**
- * **MACH7 SALES ORDERS UP 390% TO \$16.2m**
- * **CYNATA: FUJIFILM PAYS \$6.7m FOR NEW DEAL**
- * **PATRY'S: DEOXYMAB INCREASES BREAST CANCER SURVIVAL, IN MICE**
- * **MESOBLAST: 'REMESTEMCELL-L IMPROVES CHILD GvHD SURVIVAL'**
- * **NEUROSCIENTIFIC COMPLETES EMTINB PHARMACOLOGY STUDIES**
- * **AUSCANN REQUESTS FDA CPAT-01 MEETING**
- * **PHARMAUST: 24 DOGS, 1 PARTIAL RESPONSE TO MONEPANTEL**
- * **PROTEOMICS: 'CLINICAL UTILITY STUDY BACKS PROMARKERD'**
- * **VGI: JAPAN TOCOTRIENOL PATENT**
- * **ANATARA 1.8m DIRECTOR OPTIONS AGM**
- * **ONE WEEK TO AUSBIOTECH INVEST 2021, CONFERENCE**

MARKET REPORT

The Australian stock market was up 0.26 percent on Monday October 18, 2021, with the ASX200 up 19.1 points to 7,381.1 points. Eleven of the Biotech Daily Top 40 stocks were up, 22 fell, six traded unchanged and one was untraded. All three Big Caps fell.

Proteomics was the best, up 10 cents or 12.05 percent to 93 cents, with 184,847 shares traded. Genetic Signatures and Nova Eye climbed more than six percent; Actinogen was up five percent; Resonance rose 4.55 percent; Impedimed improved 3.45 percent; Immutep and Kazia were up more than two percent; with Cyclopharm, Orthocell and Volpara up by less than one percent.

Compumedics led the falls, down three cents or 7.3 percent to 38 cents, with 44,146 shares traded. Both Pharmaxis and Prescient fell 4.2 percent; Alterity, Polynovo and Telix lost three percent or more; Cynata, Medical Developments, Neuren, Oncosil, Patrys and Pro Medicus shed two percent or more; Clinuvel, CSL, Dimerix, Imugene, Nanosonics, Next Science, Opthea and Paradigm were down more than one percent; with Avita, Cochlear, Resmed, Starpharma and Universal Biosensors down by less than one percent.

PACIFIC EDGE

Pacific Edge says it has raised \$NZ23.5 million (\$A22.4 million) in an “oversubscribed” share plan at \$NZ1.35 (\$A1.31) a share, taking the total raised to \$A99.9 million. In September, Pacific Edge listed on the ASX having raised \$NZ80 million (\$A77.5 million) to further commercialize its cancer diagnostics (BD: Sep 27, 2021).

Today, the company said that it had applications for \$NZ80.0 million in shares and raised the retail offer to \$NZ23.5 million.

Pacific Edge was up five cents or 3.7 percent to \$1.39.

ALCIDION GROUP

Alcidion says it has a \$1.8 million contract with the Sydney Local Health District for the provision of its Miya Precision patient monitoring platform for its tele-health service.

Last year, Alcidion said it had a 12-month contract with Sydney Local Health District to monitor patients through the Royal Prince Alfred Virtual Hospital (BD: Jul 1, 2020).

Today, the company said the three-year agreement was an extension of the 12-month contract, with an expansion to remotely monitor patients with acute diverticulitis.

Alcidion said the agreement included bi-directional integration with Sydney Local Health District’s electronic medical record.

The company said that the use of Miya Precision in a virtual care context aimed to reduce required hospitalizations, support an increase in the numbers of patients that could be treated and improve recovery outcomes.

Alcidion said it would work with the Sydney Local Health District to introduce Miya Care to integrate data “from patient monitoring devices and patient wearable technology”.

Alcidion was up one cent or 2.9 percent to 36 cents with 2.3 million shares traded.

HERAMED

Heramed says it has raised \$2,392,047 through the issue of convertible notes, at \$1.00 each.

Heramed said that the notes would mature six months from date of issue, with interest rate set at 10 percent a year, paid in additional shares at the conversion price.

The company said that the conversion price would be at the lesser of 20 cents or a 15 percent discount to the date of a relevant event, subject to a floor of nine cents per share.

Heramed said that on conversion of the notes, investors would receive one option for every two shares issued, exercisable at 30 cents within two years.

The company said that if the notes were not converted at the maturity date of six months, they would convert automatically at a 25 percent discount to the 5-day volume-weighted average price at that time with interest paid in additional shares at the conversion price of the notes.

Heramed said that investors would also receive a one unlisted option per share, exercisable at a 200 percent premium to the conversion price, within two years.

The company said the funds would be used for the commercial roll out of the Heracare platform and the Herabeat foetal heart rate monitor.

Heramed said that PAC Partners were the lead manager for the capital raising and would receive a six percent fee and 1,000,000 options on the same terms as the options to be issued to investors.

Heramed was unchanged at 19 cents.

MACH7 TECHNOLOGIES

Mach7 says its sales orders for the three months to September 30, 2021 was up 390.9 percent to \$16.2 million, compared to the previous corresponding period.

Mach7 said the revenue was the “strongest quarterly sales order result on record” and 368 percent above the three months to June 30, 2021.

The company said that Trinity Health and Advocate Aurora Health were two of its largest customers.

Mach7 said that receipts from customers for the three months to September 30, 2021 fell 10.7 percent to \$3,354,000 compared to the three months to September 30, 2020.

The company said it had \$17,153,000 at September 30 2021 compared to \$17,809,000 at September 30, 2020.

Mach7 was up 3.5 cents or 3.65 percent to 99.5 cents.

CYNATA THERAPEUTICS

Cynata says it has received the \$US5 million (\$A6.7 million) agreed with Tokyo’s Fujifilm Corp for the change to their strategic partnership.

Last month, Cynata said that the manufacturing services agreement with Fujifilm had been terminated and a new contract manufacturing Cymerus stem cell products had been agreed (BD: Sep 30, 2021).

Cynata fell 1.5 cents or 2.4 percent to 61.5 cents.

PATRY'S

Patrys says its PAT-DX3 deoxymab antibody targeting agent, used with antibody drug conjugates, increases breast cancer survival, in mice.

In September, Patrys said that preliminary data showed that PAT-DX3, used with the anti-cancer compound monomethyl auristatin E (MMAE) “significantly inhibited tumor growth by 95 percent at day-31” (BD: Sep 15, 2021).

Today, the company said that 80 percent of the mice treated with PAT-DX3-MMAE were alive at day 60, compared to only one surviving mouse in the non-specific control antibody group.

Patrys said that PAT-DX3-MMAE “significantly increased survival compared to the control group of animals” ($p < 0.005$).

Patrys managing-director Dr James Campbell said it was “very exciting to report such positive data from our proof-of-concept study showing that Patrys’ deoxymabs may have potential as targeting agents for [antibody drug conjugates]”.

“While most [antibody drug conjugates] are based on antibodies directed against cell surface antigens that are specific for a particular tumor, our deoxymabs are attracted to the DNA that is released from most cancers as a result of the high rates of cell death and cell turnover in tumors,” Dr Campbell said. “This pre-clinical study has shown that the affinity our deoxymabs have for DNA is sufficient for them to target the delivery of cancer drugs to tumors where they can inhibit tumor growth and improve survival.”

Dr Campbell said the finding might open up new opportunities for deoxymabs.

“Additional studies will need to be performed to better understand the potential impacts of on-target and off-target toxicity using this approach, however, the results from this study have clearly demonstrated the proof-of-concept,” Dr Campbell said.

“We look forward to advancing this program as an adjunct to our planned first-in-human clinical study of PAT-DX1, which remains on track for late 2022.”

Patrys fell 0.1 cents or 2.3 percent to 4.2 cents with 22.2 million shares traded.

MESOBLAST

Mesoblast says that children treated with its remestemcel-L for graft-versus-host disease had 64 percent survival compared to 10 percent on standard-of-care.

Mesoblast said the study's senior author, the New York-based Mount Sinai Hospital's Prof James Ferrara, had said that the findings "support and extend recent studies that children with severe, [steroid refractory acute graft-versus-host disease] benefit from remestemcel-L therapy".

The company said the results came from a comparison of 25 children from Mesoblast's phase III trial of remestemcel-L in steroid-refractory acute graft versus host disease (GVHD) with 27 closely-matched children from the Mount Sinai Acute GVHD International Consortium.

In 2018, Mesoblast said that 38 of 55 children (69%) in its open-label, phase III trial of remestemcel-L for acute graft versus host disease survived to 180 days; and 33 of the 38 children (87%), who responded to its mesenchymal stem cell treatment at day-28 were alive at day-100 with the treatments well-tolerated (BD: Sep 20, 2018).

Today, the company said that the data was in an article titled 'Mesenchymal stromal cell therapy induces high responses and survival in children with steroid refractory GVHD and poor risk' published in the journal Bone Marrow Transplantation, but Biotech Daily was unable to find a link to the article, nor an abstract.

Mesoblast was unchanged at \$1.60 with two million shares traded.

NEUROSCIENTIFIC BIOPHARMACEUTICALS

Neuroscientific says it has completed pharmacology studies on Emtinb and is undertaking a four-week toxicity study to establish safety for clinical trials.

Neuroscientific said the pharmacology study examined adverse effects on the cardiovascular, respiratory, and central nervous system.

The company said that its toxicity studies were being undertaken in two different animal species, and were the final studies of its non-clinical neurology program, expected to be completed this year.

Neuroscientific said that it hoped to begin clinical development of Emtinb following the toxicity studies.

Neuroscientific fell 1.5 cents or 3.75 percent to 38.5 cents.

AUSCANN GROUP (MERGED WITH CANNPAL)

Auscann says it has requested a meeting with the US Food and Drug Administration's Centre for Veterinary Medicine for its marijuana -based CPAT-01 pain relief for dogs.

In 2020, the then Cannpal said it had opened an investigational new animal drug file for CPAT-01 pain relief treatment for dogs with osteoarthritis.

Last year Auscann and Cannpal began a merger process which was completed earlier this year (BD: Nov 16, 2020; Mar 18, 2021).

Today, Auscann said it had submitted a pre-submission conference request to the FDA, to discuss submission and investigational requirements, including the number and type of studies required to support the approval of a new animal drug application.

Auscann chief executive officer Layton Mills said the request was "a significant milestone for Auscann as we believe we are the first company globally to request a [pre-submission conference] with the FDA for a cannabinoid-based veterinary drug candidate".

Auscann fell 0.1 cents or 1.1 percent to nine cents.

PHARMAUST

Pharmaust says that one dog of 24 with naïve B-cell lymphoma has had a partial response to monepantel treatment.

Pharmaust said that 24 dogs qualified for the trial, with a further two dogs admitted but not evaluated due to incorrect dosing.

The company said that monepantel had been administered at four doses and it had calculated the optimal drug plasma range for anti-cancer activity and minimal side-effects. Pharmaust said that of the seven dogs with drug plasma levels within the optimum range, six had stable disease, and one had a partial response in which some tumors disappeared entirely.

The company said that while side-effects were minimal or not observed within the optimal range, dogs dosed below the optimal saw reduced efficacy, while dogs dosed below the optimal range exhibited occasional weight loss.

Pharmaust said that of the six dogs that achieved stable disease, five continued taking monepantel with the cortico-steroid prednisolone following the conclusion of the trial, and these dogs had “much higher than expected mean and median survival times, at 125 and 138 days, respectively”.

Pharmaust was up 0.6 cents or 6.4 percent to 10 cents.

PROTEOMICS INTERNATIONAL LABORATORIES

Proteomics says it has completed the second of two clinical utility studies required for US reimbursement of its Promarkerd diabetic kidney disease diagnostic.

Proteomics said the web-based survey of 400 primary care physicians and endocrinologists, showed that Promarkerd “significantly impacted physicians’ prescribing and monitoring decisions” for patients with type 2 diabetes.

The company said that Promarkerd tests “were more important to physicians than the current standard-of-care tests: estimated glomerular filtration rate (eGFR) and albumin-to-creatinine ratio (ACR)”.

Proteomics said that compared with no Promarkerd test results, a Promarkerd result showing a patient at high-risk of developing diabetic kidney disease was also associated with significantly higher odds of increasing monitoring frequency of a patient, prescription of sodium-glucose transport protein 2 inhibitors to lower blood glucose, replacing ibuprofen, and an increased angiotensin-converting enzyme inhibitors to lower blood pressure.

Proteomics also said that “more than three-quarters of physicians reported they were very or extremely likely to use Promarkerd in the future”.

Proteomics was up 10 cents or 12.05 percent to 93 cents.

VGI HEALTH TECHNOLOGY

VGI says the Japan Patent Office intends to grant a patent for the transmucosal delivery of tocotrienols.

The Sydney-based VGI said that once granted the patent, titled ‘Transmucosal Delivery of Tocotrienol’ would provide intellectual property rights in Japan until November 13, 2032.

The company said it had corresponding patents granted in the US, Canada, the European Union, Australia, New Zealand, Singapore and South Africa.

On the National Stock Exchange, VGI was untraded at 25 cents.

[ANATARA LIFESCIENCES](#)

Anatara says its annual general meeting will vote to grant 1,800,000 options to directors Sue MacLeman, Dr Jane Ryan and Dr David Brookes.

Anatara said that it proposed to issue 900,000 options to Dr Brookes, with 450,000 options each to Ms MacLeman and Dr Ryan, vesting in equal tranches over two years exercisable at a 50 percent premium to the 5-day volume-weighted average price to the day before the meeting and expiring on November 14, 2025.

The company said shareholders would vote on its remuneration report, the re-election of Ms MacLeman, and the approval of a ten percent placement facility.

The meeting will be held virtually on November 16, 2021 at 11am (AEST) and would be available at: web.lumiagm.com/367197181.

Anatara fell half a cent or 3.45 percent to 14 cents.

[AUSBIOTECH](#)

Ausbiotech says that bookings are open for next week's on-line Invest and Partnering 2021, the 2021 Ausbiotech conference and the business matching program.

Ausbiotech said that delegates could book one-on-one meetings with other businesses during the Auspartnering program.

The industry organization said that Auspartnering would enable "hundreds of pre-scheduled 30-minute, one-on-one meetings during the Australia's largest life science conference".

Ausbiotech also said that it would hold a trade day in which attendees could engage and network with event partners such as Abbvie, Johnson & Johnson and CSL.

The industry organisation said its final keynote speaker would be Qbiotics managing-director Dr Victoria Gordon who would discuss 'Changing the pace - raising capital to accelerate programs' following the Qbiotics capital raise of more than \$85 million dollars (BD: Jun 28, 2021).

Ausbiotech said that and Invest & Partnering 2021 would be online on October 26, with the annual conference from October 25 to 29, 2021.

To register, go to: <https://www.ausbiotechnc.org/register2021>.